Survaxm
High-grade Astrocytoma NOS
Children's Oncology GroupvaccinePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the High-grade Astrocytoma NOS cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Mayo Clinic | Phase 2 | CCC |
Efineptakin Alfa Mayo Clinic | Phase 2 | CCC |
Incb7839 Pediatric Brain Tumor Consortium | Phase 1 | CC |
Icapamespib Samus Therapeutics, Inc. | Phase 1 | CC |
Sotigalimab Pediatric Brain Tumor Consortium | Phase 1 | CC |
Lomustine Jasper Gerritsen | D |
Same molecule, other indications
Survaxm is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →